NCT03063944View on ClinicalTrials.gov

STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 17, 2017

Primary Completion Date

January 18, 2024

Study Completion Date

March 4, 2024

Conditions
Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Interventions
DRUG

STAT Inhibitor OPB-111077

Given PO

DRUG

Decitabine

Given IV

DRUG

Venetoclax

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

19171

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

Sponsors
All Listed Sponsors
collaborator

Otsuka America Pharmaceutical

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT03063944 - STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy | Biotech Hunter | Biotech Hunter